long intergenic non-protein coding RNA 1677Genealiases: []
Q-omics provides the consensus-scored LINC01677 profile across patient tissues and cancer cell-line models. LINC01677 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, LINC01677 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, LINC01677 RNA expression shows 6,341 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, KIRC, and STAD as cancer lineages where LINC01677 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01677 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01677 survival associations across molecular data types. LINC01677 RNA expression shows survival associations in the most cancer types (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01677 RNA expression–survival associations across cancer types. High LINC01677 expression shows unfavorable associations in LIHC, PCPG, HNSC, THYM and BLCA, but favorable associations in ESCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for LINC01677 RNA expression.
This table summarizes LINC01677 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01677. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01677 shows higher tumor expression in KIRC. The KIRC box plot shows higher LINC01677 RNA expression in tumor versus normal tissue (log2 FC = +0.003, t-test p = .047).
This table shows molecular features associated with LINC01677 in patient tissues and cancer cell lines. In patient samples, LINC01677 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
